Cyanide-induced parkinsonism

Summary

Cyanide-induced parkinsonism (MONDO:0017640) is a disease. A subtype of parkinsonian disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Phenotypes (HPO): 20

Clinical features

Signs & symptoms

Clinical features (HPO)

20 HPO clinical features (Orphanet curated; top 20 by frequency):

HPO ID	Term	Frequency
HP:0000298	Mask-like facies	Frequent (30-79%)
HP:0000741	Apathy	Frequent (30-79%)
HP:0001260	Dysarthria	Frequent (30-79%)
HP:0001300	Parkinsonism	Frequent (30-79%)
HP:0002063	Rigidity	Frequent (30-79%)
HP:0002067	Bradykinesia	Frequent (30-79%)
HP:0002120	Cerebral cortical atrophy	Frequent (30-79%)
HP:0002167	Abnormality of speech or vocalization	Frequent (30-79%)
HP:0002172	Postural instability	Frequent (30-79%)
HP:0002322	Resting tremor	Frequent (30-79%)
HP:0002362	Shuffling gait	Frequent (30-79%)
HP:0002425	Anarthria	Frequent (30-79%)
HP:0002527	Falls	Frequent (30-79%)
HP:0002987	Elbow flexion contracture	Frequent (30-79%)
HP:0004673	Decreased facial expression	Frequent (30-79%)
HP:0007034	Generalized hyperreflexia	Frequent (30-79%)
HP:0007311	Short stepped shuffling gait	Frequent (30-79%)
HP:0007975	Hypometric horizontal saccades	Frequent (30-79%)
HP:0011121	Abnormal skin morphology	Frequent (30-79%)
HP:0012157	Subcortical cerebral atrophy	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	cyanide-induced parkinsonism
Mondo ID	MONDO:0017640
Orphanet	306692
ICD-11	1717111858
SNOMED CT	766872002
UMLS	C4707859
MedGen	1639789
GARD	0021266
Is cancer (heuristic)	no

Disease family

This is a subtype of parkinsonian disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › basal ganglia disorder › parkinsonian disorder › cyanide-induced parkinsonism

Related subtypes (20): postencephalitic Parkinson disease, Parkinson disease, dystonia 12, Perry syndrome, X-linked parkinsonism-spasticity syndrome, early-onset parkinsonism-intellectual disability syndrome, X-linked dystonia-parkinsonism, autosomal dominant striatal neurodegeneration type 1, dystonia 16, parkinsonism-dystonia, infantile, cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome, hemiparkinsonism-hemiatrophy syndrome, carbon monoxide-induced parkinsonism, atypical juvenile parkinsonism, primary progressive freezing gait, encephalitis lethargica, parkinsonism with dementia of Guadeloupe, multiple system atrophy, parkinsonian type, parkinsonism with polyneuropathy, vascular parkinsonism

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.